drugset / Trial / NCT07111507
A Study of Tarlatamab for People With Prostate Cancer
NaSingle-groupOpen-labelTreatment
Summary
The researchers are doing this study to find out whether tarlatamab is an effective treatment for Delta-like Protein 3 (DLL3)-positive prostate cancer that has spread to other parts of your body (metastasized) and has either come back after treatment (relapsed) or not responded to treatment (refractory).
Timeline
- Start
- 2025-07-31
- Primary completion
- 2027-08-31
- Completion
- 2027-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tarlatamab | Protein / enzyme biologic | — | — |